Q3 2025 · 13F-HR
CAXTON CORPholdings as filed
Filed 2025-11-14 · accession 0000919574-25-006891
$22.9M
Reported value
12
Positions
2025-09-30
Period end
The Brief · CAXTON CORP · Q3 2025
AI · grounded in 13F
CAXTON CORP established a new position in RZLT valued at $18.7M. The fund also initiated a position in GLD for $2.6M. Additional new holdings include BRK/B at $327,454 and BRD1EUR at $318,459.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76200L309 | RZLT | REZOLUTE INC | $18.7M | 81.7% | 1,986,818 | Common | SOLE |
| 78463V107 | GLD | SPDR GOLD TR | $2.6M | 11.3% | 7,286 | Common | SOLE |
| 084670702 | BRK/B | BERKSHIRE HATHAWAY INC DEL | $327,454 | 1.43% | 651 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $318,459 | 1.39% | 27,011 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $268,106 | 1.17% | 13,097 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $187,260 | 0.82% | 53,503 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $172,760 | 0.76% | 10,941 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $137,887 | 0.60% | 22,981 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $115,084 | 0.50% | 17,332 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $26,557 | 0.12% | 16,393 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $21,979 | 0.10% | 10,935 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $17,829 | 0.08% | 18,403 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.